Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.

Jamie E. Chaft,Daniel B. Costa,Alona Muzikansky,Joseph B. Shrager,Michael Lanuti,James Huang,Kavitha Ramchandran,Deepa Rangachari,Mark S. Huberman,Zofia Piotrowska,Mark G. Kris,Christopher G. Azzoli,Lecia V. Sequist,Joel W. Neal

Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.

2019

Jamie E. Chaft
Daniel B. Costa
Alona Muzikansky
Joseph B. Shrager
Michael Lanuti
James Huang
Kavitha Ramchandran
Deepa Rangachari
Mark S. Huberman
Zofia Piotrowska
Mark G. Kris
Christopher G. Azzoli
Lecia V. Sequist
Joel W. Neal

8507Background: EGFR tyrosine kinase inhibitors are superior to chemotherapy in patients with advanced EGFR+ lung cancers. In the adjuvant setting, erlotinib for two years improves recurrence free ...

Keywords:

Erlotinib
Afatinib
Adjuvant
Phases of clinical research
EGFR Tyrosine Kinase Inhibitors
Lung
Mutant
Pathology
Oncology
Internal medicine
Chemotherapy
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations